Randy Burd, Ph.D. is the Director of Research at BerylStone and an Associate Professor at University of Arizona. Randy received his Ph.D. in Molecular and Cellular Biophysics in 1998 from the Roswell Park Cancer Institute in Buffalo, New York and has worked in the area of pharmaceutical and biotechnology research for over a decade. In 2002 he was appointed the director of Pre-Clinical Therapeutics at Thomas Jefferson University. In 2005 he was recruited to the University of Arizona. Randy joined BerylStone in 2011 and currently co-manages BerylStone Investment's Managed Portfolios. Twitter- @randymburd Linkedin- http://www.linkedin.com/in/rburd
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Steven currently focuses his analyses primarily on the valuation of smaller biotechs (100MM to 1 BB market cap) and utilizes all sources of information, including conversations with management, peer-reviewed publications, SEC filings, and all available primary and secondary research.
Steven is currently a consultant for a New York based life science focused consultancy, and brings a strong scientific and financial background to his current position.
Previously, Steven earned a Ph.D. from the Scripps Research Institute and an M.A. from Columbia University, with extensive work in the field of synthetic and medicinal chemistry, publishing several papers in prestigious peer-reviewed journals. He is also pursuing the CFA designation, and has completed exam level 2.
Please email me with any questions, comments, and investment ideas. (stevenb29 at gmail.com)
John Hodge is an active trader who follows the technology/biotech sector specifically. I have been successfully trading stocks for the last 16 years and still thank those that pointed me in the direction of Qualcomm and Amgen many years ago. I believe research and timing is the key to long term goal attainment in the market.
Individual investor. I have been trying to create wealth for me and my family for over 30 years. The market correction since the early 80's have paired gains, plus some bad choices.
Still looking for something that works.
I hold BS degrees in Biology and Environmental Policy in addition to an M.Ed in Science Education. I have experience as a researcher in the biotech sector. Currently, I teach Biology courses as well as publish articles and research in the fields of science, education and public policy.
Long/Short Equity Portfolio Manager at Emerald Waves Investments, LLC. Former Director of Research at Biondo Investment Advisors, and investment professional at Federated Investors and Sands Capital Management. Also previously worked in investment banking at Merrill Lynch and First Union Securities. Graduated from Duke University and Darden Graduate School of Business Administration, University of Virginia, and is a CFA Charterholder.
I am a pharmacist for a large research hospital system based in Ohio. I generally am interested in the pharmaceutical industry as well as large income producing companies. I am long ATHX, PFE, MNTA, and ABLYF